Janjigian, Y. Y. Et Al. 2023. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. LANCET , vol.402, no.10418 , 2197-2208.

Janjigian, Y. Y., Kawazoe, A., Bai, Y., Xu, J., Lonardi, S., Metges, J. P., ... Yanez, P.(2023). Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. LANCET , vol.402, no.10418, 2197-2208.

Janjigian, Yelena Et Al. "Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial," LANCET , vol.402, no.10418, 2197-2208, 2023

Janjigian, Yelena Y. Et Al. "Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial." LANCET , vol.402, no.10418, pp.2197-2208, 2023

Janjigian, Y. Y. Et Al. (2023) . "Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial." LANCET , vol.402, no.10418, pp.2197-2208.

@article{article, author={Yelena Y. Janjigian Et Al. }, title={Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial}, journal={LANCET}, year=2023, pages={2197-2208} }